镭-223的影像学与剂量测定:个体化治疗的潜力
本文综述镭-223(223Ra)治疗前列腺癌骨转移时影像学与剂量测定的应用。目前223Ra按标准固定给药、依体重调整;尽管γ射线仅占总发射能量1%,越来越多报告提示定量影像可行并支持患者特异性剂量测定,从而有望据此优化治疗。
要点
- 223Ra发射的γ射线仅占总能量1%,但定量影像仍可行,可支持患者特异性剂量测定。
- 当前223Ra按标准固定给药、根据体重调整;个体化给药是潜在优化方向。
- 定量影像能活体显示治疗药物的摄取与滞留,为放疗药物个体化提供依据。
核心结论
- 越来越多报告提示定量影像可行并支持患者特异性剂量测定,可据此优化223Ra治疗,以确保临床与成本效益。
研究设计与样本
- 综述,检索范围与纳入文献数原文未报告;讨论223Ra治疗前列腺癌骨转移中影像与剂量测定的应用。
临床应用与阅片要点
- 223Ra目前采用标准固定给药、根据患者体重调整。
- 定量影像可活体评估治疗药物摄取与滞留,是患者特异性剂量测定的基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Radium-223 (223Ra) offers a new option for the treatment of bone metastases from prostate cancer. As cancer treatment progresses towards personalization, the potential for an individualized approach is exemplified in treatments with radiotherapeutics due to the unique ability to image in vivo the uptake and retention of the therapeutic agent. This is unmatched in any other field of medicine. Currently, 223Ra is administered according to standard fixed administrations, modified according to patient weight. Although gamma emissions comprise only 1% of the total emitted energy, there are increasing reports that quantitative imaging is feasible and can facilitate patient-specific dosimetry. The aim of this article is to review the application of imaging and dosimetry for 223Ra and to consider the potential for treatment optimization accordingly, in order to ensure clinical and cost effectiveness of this promising agent.
引用
- Flux GD. Imaging and dosimetry for radium-223: the potential for personalized treatment. Br J Radiol. 2017. PMID: 28654303. doi:10.1259/bjr.20160748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。